Baseline characteristics
| N = 172; preleukapheresis, unless specified . | n (%) or median (IQR) . |
|---|---|
| Age, y | 62 (51-68) |
| Sex | |
| Male | 98 (57) |
| Female | 74 (43) |
| Race | |
| White | 131 (76) |
| Asian | 10 (6) |
| Black | 9 (5) |
| Other | 5 (3) |
| Unknown | 17 (10) |
| ECOG | |
| 0 | 43 (25) |
| 1 | 96 (56) |
| 2 | 26 (15) |
| 3 | 5 (3) |
| Unknown | 2 (1) |
| Histology | |
| DLBCL | 122 (71) |
| DLBCL (transformed FL) | 32 (19) |
| PMBCL | 13 (8) |
| Mantle cell lymphoma | 3 (2) |
| T-cell/histiocyte-rich large B-cell lymphoma | 1 (<1) |
| Burkitt lymphoma | 1 (<1) |
| Cell of origin∗ | |
| GCB | 101 (60) |
| ABC | 49 (29) |
| Unknown | 18 (11) |
| Double hit (FISH)∗ | |
| Yes | 42 (25) |
| No | 113 (67) |
| Unknown | 13 (8) |
| Primary refractory | 75 (43) |
| Previous no. of lines of therapy | 3 (2-3) |
| 1 | 2 (1) |
| 2 | 75 (44) |
| 3 | 55 (32) |
| 4 | 16 (9) |
| 5 | 15 (9) |
| 6 | 4 (2) |
| 7 | 3 (2) |
| 8 | 2 (1) |
| Previous transplant | 23 (13) |
| Stage | |
| Early (I-II) | 45 (26) |
| Advanced (III-IV) | 127 (74) |
| Extranodal disease | |
| Yes | 116 (67) |
| No | 49 (28) |
| Unknown | 7 (4) |
| CNS involvement | |
| Yes | 17 (10) |
| No | 155 (90) |
| Elevated preleukapheresis LDH | |
| Yes | 113 (66) |
| No | 57 (33) |
| Unknown | 2 (1) |
| Elevated preinfusion LDH | |
| Yes | 76 (44) |
| No | 83 (48) |
| Unknown | 13 (8) |
| Largest lesion maximum diameter, cm† | 6.7 (4.1-12.2) |
| Largest lesion ≥5 | 98 (66) |
| Largest lesion ≥7.5 | 73 (49) |
| Largest lesion ≥10 | 64 (39) |
| Maximum SUV ≥10‡ | 116 (81) |
| CAR-T construct | |
| Axi-cel | 126 (73) |
| Tisa-cel | 42 (24) |
| Brexucabtagene autoleucel | 4 (2) |
| Lymphodepletion regimen | |
| Fludarabine/cyclophosphamide | 143 (83) |
| Bendamustine | 28 (16) |
| Cyclophosphamide | 1 (<1) |
| Bridging systemic therapy (excluding steroids) | 60 (35) |
| N = 172; preleukapheresis, unless specified . | n (%) or median (IQR) . |
|---|---|
| Age, y | 62 (51-68) |
| Sex | |
| Male | 98 (57) |
| Female | 74 (43) |
| Race | |
| White | 131 (76) |
| Asian | 10 (6) |
| Black | 9 (5) |
| Other | 5 (3) |
| Unknown | 17 (10) |
| ECOG | |
| 0 | 43 (25) |
| 1 | 96 (56) |
| 2 | 26 (15) |
| 3 | 5 (3) |
| Unknown | 2 (1) |
| Histology | |
| DLBCL | 122 (71) |
| DLBCL (transformed FL) | 32 (19) |
| PMBCL | 13 (8) |
| Mantle cell lymphoma | 3 (2) |
| T-cell/histiocyte-rich large B-cell lymphoma | 1 (<1) |
| Burkitt lymphoma | 1 (<1) |
| Cell of origin∗ | |
| GCB | 101 (60) |
| ABC | 49 (29) |
| Unknown | 18 (11) |
| Double hit (FISH)∗ | |
| Yes | 42 (25) |
| No | 113 (67) |
| Unknown | 13 (8) |
| Primary refractory | 75 (43) |
| Previous no. of lines of therapy | 3 (2-3) |
| 1 | 2 (1) |
| 2 | 75 (44) |
| 3 | 55 (32) |
| 4 | 16 (9) |
| 5 | 15 (9) |
| 6 | 4 (2) |
| 7 | 3 (2) |
| 8 | 2 (1) |
| Previous transplant | 23 (13) |
| Stage | |
| Early (I-II) | 45 (26) |
| Advanced (III-IV) | 127 (74) |
| Extranodal disease | |
| Yes | 116 (67) |
| No | 49 (28) |
| Unknown | 7 (4) |
| CNS involvement | |
| Yes | 17 (10) |
| No | 155 (90) |
| Elevated preleukapheresis LDH | |
| Yes | 113 (66) |
| No | 57 (33) |
| Unknown | 2 (1) |
| Elevated preinfusion LDH | |
| Yes | 76 (44) |
| No | 83 (48) |
| Unknown | 13 (8) |
| Largest lesion maximum diameter, cm† | 6.7 (4.1-12.2) |
| Largest lesion ≥5 | 98 (66) |
| Largest lesion ≥7.5 | 73 (49) |
| Largest lesion ≥10 | 64 (39) |
| Maximum SUV ≥10‡ | 116 (81) |
| CAR-T construct | |
| Axi-cel | 126 (73) |
| Tisa-cel | 42 (24) |
| Brexucabtagene autoleucel | 4 (2) |
| Lymphodepletion regimen | |
| Fludarabine/cyclophosphamide | 143 (83) |
| Bendamustine | 28 (16) |
| Cyclophosphamide | 1 (<1) |
| Bridging systemic therapy (excluding steroids) | 60 (35) |
ABC, activated B-cell like; DLBCL, diffuse large B-cell lymphoma; FISH, fluorescence in situ hybridization; FL, follicular lymphoma; GCB, germinal center B-cell like; PMBCL, primary mediastinal B-cell lymphoma.
Excluding 3 mantle cell and 1 Burkitt lymphoma cases.
Largest lesion maximum diameter (cm), largest lesion ≥5 cm, and largest lesion ≥7.5 cm were unavailable for 23 patients; however, largest lesion ≥10 cm was unavailable for only 6 patients.
Unavailable for 29 patients.